»¶ÀÖ¶·µØÖ÷_Õ©½ð»¨ÓÎÏ·

JIA Qi, ZHANG Weiwei,LIU Qiwei

( Department of Tumor ¢ò, the First People¡äs Hospital of Nanyang, Nanyang 

473000, China)

Abstract Objective To observe the effect of lentinan assisted FOLFOX4 chemotherapy on the short-term efficacy and long-term prognosis of advanced gastric cancer. Methods 100 patients with advanced gastric cancer were selected as the research subjects, and randomly divided into two groups using a random number table method, with 50 cases in each group. Both groups of patients were received FOLFOX4 chemotherapy, while the combination group were received adjuvant treatment with lentinan. After treatment, both groups were followed up for 1 year to compare their short-term efficacy and prognosis. Results Under different treatment regimens, the levels of vascular endothelial growth factor ( VEGF) and interleukin-10 ( IL-10 ) in the combination group were lower than those in the chemotherapy group, showing a statistically significant difference ( P<0.05) ; the subsets of T lymphocytes CD3+ , CD4+ , CD4+/CD8+ were all higher than those in the chemotherapy group ( P < 0. 05) ; the levels of carcinoembryonic antigen ( CEA) , carbohydrate antigen 199 ( CA199) , and carbohydrate antigen 242 ( CA242) were all lower than those in the chemotherapy group ( P<0.05) ; the objective response rate ( ORR) and disease control rate ( DCR) were higher than those in the chemotherapy group ( P<0.05) ; as of the end of follow-up, the median progression free survival ( PFS) and median overall survival ( OS) in the combination group were higher than those in the chemotherapy group ( P < 0. 05 ) . Conclusion Lentinan assisted FOLFOX4 chemotherapy enhances the short-term efficacy of advanced gastric cancer patients and hapositive implications for improving their short-term prognosis.

Keywords: advanced gastric cancer; lentinan; FOLFOX4 chemotherapy; recent therapeutic effects; shortterm prognosis

DOI:10.19296/j.cnki.1008-2409.2024-03-014

PDF download:click to download